Cargando…
Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
Autores principales: | Podola, L, Bauer, A, Haule, A, Sudi, L, Nilsson, C, Godoy-Ramirez, K, Mann, P, Missanga, M, Kaluwa, B, Maboko, L, Lueer, C, Mwakatima, M, Aboud, S, Bakari, M, Currier, J, Robb, M, McCormack, S, Joseph, S, Lyamuya, E, Hoelscher, M, Wahren, B, Sandström, E, Biberfeld, G, Geldmacher, C, Kroidl, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441674/ http://dx.doi.org/10.1186/1742-4690-9-S2-P273 |
Ejemplares similares
-
Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012) -
Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial
por: Munseri, Patricia. J., et al.
Publicado: (2015) -
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
por: Joachim, Agricola, et al.
Publicado: (2016) -
Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design
por: Viegas, Edna O., et al.
Publicado: (2018) -
High prevalence of ECG variations and abnormalities in young and healthy TaMoVac 01 HIV vaccine trial volunteers from Tanzania
por: Mann, PJ, et al.
Publicado: (2012)